Update on the management of the pregnant patient with antiphospholipid antibody
- Lisa R. Sammaritano MD
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Management of the pregnant patient with antiphospholipid antibody (aPL) is reviewed, with emphasis on recent randomized controlled clinical trials. These support the use of subcutaneous heparin and low dose aspirin, current standard therapy for women with aPL and a history of fetal loss. Prednisone is rarely used due to high risk of maternal and fetal morbidity. Intravenous immunoglobulin may represent an important additional therapy for women who fail aspirin and heparin. Patients with a history of thrombosis require full, therapeutic anticoagulation during pregnancy. Recommendations are less clear for newly described antibodies to phospholipid-binding protein, for low titer antibodies, and for infertility treatment in the setting of aPL.
- Wilson WA, Gharavi AE, Koike T, et al.: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999, 42:1309–1311. The first published criteria for antiphospholipid syndrome, formulated at the 8th International Symposium on Antiphospholipid Antibodies in Sapporo, Japan, 1998. CrossRef
- Branch DW, Silver R, Pierangeli S, van Leeuwen I, Harris EN: Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol 1997, 89:549–555. Serum antibody binding against six phospholipids (cardiolipin, phosphatidic acid, phosphatidylserine, phosphatidylcholine, phosphatidylinosital, and phosphatidylethanolamine) was evaluated in three groups of women: 147 women with recurrent pregnancy loss negative for anticardiolipin antibody (aCL) and lupus anticoagulant (LA), 104 healthy controls, and 43 women with well-characterized antiphospholipid syndrome. Women with recurrent pregnancy loss were no more likely than fertile controls to have elevated levels of antiphospholipid antibodies once aCL and LA were excluded. Testing for antiphosphospholipid antibodies other than LA and aCL is not clinically useful in the evaluation of recurrent pregnancy loss. CrossRef
- Parke AL, Wilson D, Maier D: The prevalence of antiphospholipid antibodies in women with recurrent spontaneous abortion, women with successful pregnancies, and women who have never been pregnant. Arthritis Rheum 1991, 34:1231–1235. CrossRef
- McNeil HP, Simpson RJ, Chesterman CN, Krilis SA: Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990, 87:4120–4125. CrossRef
- Galli M: Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome? J Autommunity 2000, 15:101–106. CrossRef
- Satoh A, Suzuki K, Takayama E, et al.: Detection of anti-Annexin IV and Annexin V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 1999, 26:1715–1720.
- Harris EN, Spinnato JA: Should anticardiolipin tests be performed in otherwise healthy pregnant women? Am J Obstet Gynecol 1991, 165:1272–1277.
- Ramsey-Goldman R, Kutzer JE, Kuller LH, et al.: Previous pregnancy outcome is an important determinant of subsequent pregnancy outcome in women with systemic lupus erythematosus. Am J Reprod lmmunol 1992, 28:195–198.
- Lee RM, Emlen W, Scott JR, Branch DW, Silver RM: Anti-b2-glycoprotein I antibodies in women with recurrent spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome. Am J Obstet Gynecol 1999, 181:642–648. CrossRef
- Franklin RD, Hollier N, Kutteh WH: Beta-2 glycoprotein 1 as a marker of antiphospholipid syndrome in women with recurrent pregnancy loss. Fertil Steril 2000, 73:531–535. Sera from 90 women with recurrent pregnancy loss (45 with and 45 without aPL) were tested for the presence of antibodies to b2GPI. Twenty-two percent of the women with APS were positive for antibodies to b2GPI compared with 2% in the non-aPL-positive group. These data suggest that anti-b2GPI antibodies are less sensitive than traditional aPL for the diagnosis of APS. CrossRef
- Martinelli I, Taioli E, Cetin I, et al.: Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000, 343:1015–1018. CrossRef
- Gris JC, Quire I, Monpeyroux F, et al.: Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent-the Nimes Obstetricians and Haemotologists Study 5 (NOHA5). Thrombosis Haemostasis 1999, 81:891–899. A case-control study on the prevalence of heritable thrombophilic defects, aPL, and the C677T mutation in the MTHFR gene in patients with unexplained late fetal loss versus controls. At least one biologic risk factor for venous thrombosis was identified in 21% of patients versus 4% of controls. The crude odds ratio for still births associated with any positive biologic risk factor for venous thrombosis was 5.5.
- Espana F, Villa P, Mira Y, et al.: Factor V Leiden and antibodies against phospholipid and protein S in a young woman with recurrent thromboses and abortion. Haematologica 1999, 84:80–84.
- Kaleli K, Kaleli I, Aktan E, Turan C, Aksit F: Antiphospholipid antibodies in pre-eclamptic women. Gynecol Obstet Invest 1998, 45:81–84. Thirty-six eclamptic and 30 healthy pregnant women were enrolled in this study to define the prevalence of aPL in eclamptic women and the rates of intrauterine growth retardation and fetal death in aPLpositive and aPL-negative eclamptic women. Twenty-five percent of eclamptic women were positive for aPL versus 6% of controls. In addition, results suggested that the presence of aPL in eclamptic women increased the risk for intrauterine fetal death. CrossRef
- Magid MS, Kaplan C, Sammaritano LR, et al.: Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol 1998, 179:226–234. Forty placentae from 33 women with SLE or aPL antibody were studied prospectively to distinguish the effect of each on gestational outcome and placental pathologic conditions. Placental findings were of ischemic-hypoxic change, decidual vasculopathy, decidual and fetal thrombi, chronic villitis, and decreased placental weight. Extensive infarction and fetal death were important antiphospholipid antibody-related findings. CrossRef
- Field SL, Brighton TA, McNeil HP, Chesterman CN: Recent insights into antiphospholipid antibody-mediated thrombosis. Bailliere Best Pract Clin Haematol 1999, 12:407–422. Comprehensive review of proposed mechanisms of aPL-induced thrombosis including more recent insights into the role of b2GPI as an anticoagulant, procoagulant effects of aPL on the protein C system, aPL/prothrombin interactions, and cellular expression of tissue factor.
- Rand JH, Wu XX, Andree HA, et al.: Pregnancy loss in the antiphospholipid-antibody syndrome-a possible thrombogenic mechanism. N Engl J Med 1997, 337:154–160. CrossRef
- La Rosa L, Meroni PL, Tincani A, et al.: Beta-2-glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid antibody syndrome. J Rheumatol 1994, 21:1684–1693.
- Roubey RAS: Tissue factor pathway and the antiphospholipid syndrome. J Autommunity 2000, 15:217–220. CrossRef
- Xu C, Mao D, Holers VM, et al.: A critical role for murine complement regulator CRRY in fetomaternal tolerance. Science 2000, 287:498–501. CrossRef
- Sthoeger ZM, Mozes E, Tartakovsky B: Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. Proc Nat Acad Sci USA 1993, 90:6464–6467. CrossRef
- Di Simone N, Meroni PL, del Papa N, et al.: Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered b2-glycoprotein I. Arthritis Rheum 2000, 43:140–150. CrossRef
- Pierro E, Cirino G, Bucci MR, et al.: Antiphospholipid antibodies inhibit prostaglandin release by decidual cells of early pregnancy: possible involvement of extracellular secretory phospholipase A2. Fertil Steril 1999, 71:342–346. CrossRef
- Gleicher N, Pratt D, Dudkiewicz AB: Autoantibodies in in vitro fertilization patients. Fertil Steril 1992, 58:863.
- Kutteh WH, Rote NS, Silver R: Antiphospholipid antibodies and reproduction: the antiphospholipid antibody syndrome. Am J Reprod Immunol (Copenhagen) 1999, 41:133–152.
- Sher G, Feinman M, Zouves C, et al.: High fecundity rates following in vitro fertilization and embryo transfer in antiphospholipid antibody seropositive women treated with heparin and aspirin. Human Reprod 1994, 9:2278–2283.
- Guballa N, Sammaritano L, Schwartzman S, Buyon J, Lockshin M: Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 2000, 43:550–556. CrossRef
- Le Thi Huong D, Wechsler B, Edelman P, et al.: Postpartum cerebral infarction associated with aspirin withdrawal in the antiphospholipid syndrome. J Rheumatol 1993, 20:1229–1232.
- Kon SP, Kwan JT, Raftery MJ: Reversible renal failure due to antiphospholipid antibody syndrome, preeclampsia and renal thrombotic microangiopathy. Clin Nephrol 1995, 44:271–273.
- Amant F, Spitz B, Arnout J, Van Assche FA: Hepatic necrosis and haemorrhage in pregnant patients with antiphospholipid antibodies. Lupus 1997, 6:552–555.
- Segal S, Shenhave S, Segal O, Zohav E, Gemer O: Budd-Chiari syndrome complicating severe preeclampsia in a parturient with primary antiphospholipid syndrome. Eur J Obstet Gynecol Reprod Biol 1996, 68:227–229. CrossRef
- Nagayuma K, Izumi N, Miyasaka Y, et al.: Hemolysis, elevated liver enzymes and low platelets syndrome associated with primary antiphospholipid antibody syndrome. Int Med 1997, 36:661–666.
- Kang AH, Graves CR: Libman-Sacks endocarditis in a pregnant woman with acute respiratory distress syndrome. Obstet Gynecol 1999, 93:819–821. CrossRef
- Hardwick RH, Slade RR, Smith PA, Thompson MH: Laparoscopic splenectomy in pregnancy. J Laparo Adv Surg Tech (A) 1999, 9:439–440. CrossRef
- Wislowska M: Successful treatment of catastrophic antiphospholipid syndrome in a pregnant woman [letter]. Clin Exp Rheumatol 1999, 17:261.
- Navarro F, Dona-Naranjo MA, Villanueva I: Neonatal antiphospholipid syndrome. J Rheumatol 1997, 24:1240–1241.
- Ruffati A, Dalla Barba B, Del Ross T, et al.: Outcome of fifty-five newborns of antiphospholipid antibody-positive mothers treated with calcium heparin during pregnancy. Clin Exp Rheumatol 1998, 16:605–610.
- Langevitz P, Livneh A, Dulitzki M, et al.: Outcome of pregnancy in three patients with primary antiphospholipid syndrome after stroke. Semin Arthritis Rheum 1998, 28:26–30. CrossRef
- Silver RM, Draper ML, Byrne JLB, et al.: Unexplained elevations of maternal serum alpha-fetoprotein in women with antiphospholipid antibodies: a harbinger of fetal death. Obstet Gynecol 1994, 83:150–157.
- Cowchock S, Reece EA: Do low risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Trial. Am J Obstet Gynecol 1997, 176:1099–1100. CrossRef
- Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L: Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone to low dose heparin treatment. Am J Obstet Gynecol 1992, 166:1318–1323. The first randomized, controlled study comparing low-dose aspirin and prednisone (40 mg/d) with low-dose aspirin and heparin (aPTT at upper limits of normal, average daily dose 8500 units twice daily) in 20 aPL-positive women with a history of fetal loss. Success rates were 75% in both groups. Serious maternal morbidity and preterm birth were higher in the group treated with prednisone.
- Rai R, Cohen H, Dave M, Regan L: Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997, 314:253–257. Randomized controlled trial of aspirin 75 mg/day versus aspirin plus unfractionated heparin (5000 units twice daily) in 90 pregnancies. Women with systemic lupus erythematosus or a history of thrombosis were excluded. Success rates for aspirin alone versus aspirin and heparin were 42% and 71%, respectively. Most miscarriages occurred in the first trimester.
- Kutteh WH: Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996, 174:1584–1589. Randomized controlled trial of low-dose aspirin versus aspirin plus unfractionated heparin at 1.5 × baseline aPTT in 50 patients without a history of systemic lupus erythematosus or thrombosis. Average heparin dose was 13,500 units twice daily. Success rates for aspirin alone versus aspirin plus heparin were 44% and 80%, respectively. CrossRef
- Kutteh WH, Ermel LD: A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol 1996, 35:402–407. Randomized controlled trial of low-dose aspirin plus one or two doses of unfractionated heparin: 1.2–1.5 × aPTT (average dose 13,200 units twice daily) versus aPTT at upper limits of normal (average dose 8127 units twice daily). Low-dose heparin is as effective as high-dose heparin (76% vs 80% success rates) for antiphospholipid antibodyassociated recurrent pregnancy loss.
- Inbar O, Blank M, Faden D, et al.: Prevention of fetal loss in experimental antiphospholipid syndrome by low-molecular weight heparin. Am J Obstet Gynecol 1993, 169:423–426.
- DiSimone N, Ferrazzani S, Castellani R, et al.: Heparin and low-dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera. Hum Reprod 1997, 12:2061–2065. CrossRef
- Sherer Y, Levy Y, Shoenfeld Y: Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford) 2000, 39:421–426. CrossRef
- Branch DW, Peaceman AM, Druzin M, et al.: A multicenter placebo-controlled study of intravenous immunoglobulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 2000, 182:122–127. CrossRef
- Arnout J, Spitz B, Wittevrongel C, et al.: High dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: immunological changes associated with a successful outcome. Thromb Haemostas 1994, 71:741–747.
- Nakamura Y, Yoshida K, Itoh S, et al.: Immunoadsorption plasmapheresis as a treatment for pregnancy complicated by systemic lupus erythematosus with positive antiphospholid antibodies. Am J Reprod Immunol (Copenhagen) 1999, 41:307–311. Eight pregnancies in seven patients with systemic lupus erythematosus positive for lupus anticoagulant were treated with low-dose aspirin, low-dose prednisone, and immunoadsorption plasmapheresis (IA). No significant complications related to IA were noted. Survival rate was 87%: seven of eight pregnancies resulted in preterm live births, with a single fetal loss at 24 weeks. IA merits further consideration for aPL-positive women with fetal loss unresponsive to standard therapies.
- Barbour LA, Kick SD, Steiner JF, et al.: A prospective study of heparin induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994, 170:862–869.
- Silver RM, Draper ML, Scott JR, et al.: Clinical consequences of antiphospholipid antibodies: an historic cohort study. Obstet Gynecol 1994, 83:372–377.
- Erkan D, Merrill JT, Yazici Y, et al.: High thrombosis rate after fetal loss in antiphospholipid syndrome-effective prophylaxis with aspirin [abstract]. Arthritis Rheum 2000, 43:s280. Retrospective review of the course of women with history of fetal loss and aPL but no history of thrombosis. Over 10 years of follow-up, 60% of those who did not continue aspirin developed thrombotic events as compared with 9% of women who stayed on long-term, low-dose aspirin.
- Shoenfeld Y, Sherer Y, Blank M: Antiphospholipid syndrome in pregnancy-animal models and clinical implications. Scand J of Rheumatol 1998, 107:33–36. Comprehensive review of spontaneous and induced modes of APS in mice, summarizing the literature regarding animal models of APS in pregnancy and discussing these in relation to treatment options for women having pregnancy complications of APS.
- Fishman P, Falach-Vaknine E, Zigelman R, et al.: Prevention of fetal loss in experimental anti-phospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest 1993, 91:1834–1837. CrossRef
- Blank M, Shoenfeld Y, Cabilly S, et al.: Prevention of experimental antiphospholipid syndrome and endothelial activation by synthetic peptides. Proc Nat Acad Sci USA 1999, 96:5164–5168. CrossRef
- Update on the management of the pregnant patient with antiphospholipid antibody
Current Rheumatology Reports
Volume 3, Issue 3 , pp 213-221
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Hospital for Special Surgery, Weill Medical College of Cornell University, 535 East 70th Street (777W), 10021, New York, NY, USA